Citations to this article
Erin George, … , Katherine L. Nathanson, Fiona Simpkins
Published January 12, 2017
Citation Information: JCI Insight. 2017;2(1):e89760. https://doi.org/10.1172/jci.insight.89760.
Citation Information: JCI Insight. 2017;2(1):e89760. https://doi.org/10.1172/jci.insight.89760.
Abstract
Approximately 50% of high-grade serous ovarian cancers (HGSOCs) have defects in genes involved in homologous recombination (HR) (i.e.,
Authors
Erin George, Hyoung Kim, Clemens Krepler, Brandon Wenz, Mehran Makvandi, Janos L. Tanyi, Eric Brown, Rugang Zhang, Patricia Brafford, Stephanie Jean, Robert H. Mach, Yiling Lu, Gordon B. Mills, Meenhard Herlyn, Mark Morgan, Xiaochen Zhang, Robert Soslow, Ronny Drapkin, Neil Johnson, Ying Zheng, George Cotsarelis, Katherine L. Nathanson, Fiona Simpkins
Total citations by year
Citation information
Citations to this article (45)
| Title and authors | Publication | Year |
|---|---|---|
|
The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.
Kolahi Azar H, Gharibshahian M, Rostami M, Mansouri V, Sabouri L, Beheshtizadeh N, Rezaei N |
Journal of biological engineering | 2024 |
|
Targeting CCNE1 amplified ovarian and endometrial cancers by combined inhibition of PKMYT1 and ATR
Xu H, George E, Gallo D, Medvedev S, Wang X, Kryczka R, Hyer ML, Fourtounis J, Stocco R, Aguado-Fraile E, Petrone A, Yin SY, Shiwram A, Anderson M, Kim H, Liu F, Marshall CG, Simpkins F |
Research square | 2024 |
|
A B7-H4 targeting antibody-drug conjugate shows anti-tumor activity in PARPi and platinum resistant cancers with B7-H4 expression
Gitto SB, Whicker M, Davies G, Kumar S, Kinneer K, Xu H, Lewis A, Mamidi S, Medvedev S, Kim H, Anderton J, Tang EJ, Ferman B, Coats S, Wilkinson RW, Brown E, Powell DJ Jr, Simpkins F |
Clinical cancer research | 2024 |
|
Exogenous Metabolic Modulators Improve Response to Carboplatin in Triple-Negative Breast Cancer
Ho AN, Kiesel VA, Gates CE, Brosnan BH, Connelly SP, Glenny EM, Cozzo AJ, Hursting SD, Coleman MF |
Cells | 2024 |
|
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer
Xu H, Gitto SB, Ho GY, Medvedev S, Shield-Artin K, Kim H, Beard S, Kinose Y, Wang X, Barker HE, Ratnayake G, Hwang WT, Hansen RJ, Strouse B, Milutinovic S, Hassig C, Wakefield MJ, Vandenberg CJ, Scott CL, Simpkins F |
iScience | 2024 |
|
Patient-derived models facilitate precision medicine in liver cancer by remodeling cell-matrix interaction
Chen K, Li Y, Wang B, Yan X, Tao Y, Song W, Xi Z, He K, Xia Q |
Frontiers in immunology | 2023 |
|
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Bouberhan S, Bar-Peled L, Matoba Y, Mazina V, Philp L, Rueda BR |
2023 | |
|
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D\u2019Andrea K, Wubbenhorst B, Hallberg D, O\u2019Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F |
Research square | 2023 |
|
Three-Dimensional Modelling of Ovarian Cancer: From Cell Lines to Organoids for Discovery and Personalized Medicine
C Yee, K Dickson, M Muntasir, Y Ma, D Marsh |
Frontiers in Bioengineering and Biotechnology | 2022 |
|
Patient-derived tumor models are attractive tools to repurpose drugs for ovarian cancer treatment: Pre-clinical updates
M Cybula, M Bieniasz |
Oncotarget | 2022 |
|
Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
T Tanaka, R Nishie, S Ueda, S Miyamoto, S Hashida, H Konishi, S Terada, Y Kogata, H Sasaki, S Tsunetoh, K Taniguchi, K Komura, M Ohmichi |
Journal of Clinical Medicine | 2022 |
|
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application
A Ciucci, M Buttarelli, A Fagotti, G Scambia, D Gallo |
Cellular and Molecular Life Sciences | 2022 |
|
Harnessing preclinical models for the interrogation of ovarian cancer
Qin T, Fan J, Lu F, Zhang L, Liu C, Xiong Q, Zhao Y, Chen G, Sun C |
Journal of experimental & clinical cancer research : CR | 2022 |
|
Zebrafish patient-derived xenografts accurately and quickly reproduce treatment outcomes in non–small cell lung cancer patients
Hua X, Wu X, Xu K, Zhan P, Liu H, Zhang F, Lv T, Song Y |
Experimental Biology and Medicine | 2022 |
|
CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models
H Xu, E George, Y Kinose, H Kim, JB Shah, JD Peake, B Ferman, S Medvedev, T Murtha, CJ Barger, KM Devins, K DAndrea, B Wubbenhorst, LE Schwartz, WT Hwang, GB Mills, KL Nathanson, AR Karpf, R Drapkin, EJ Brown, F Simpkins |
Reproduction | 2021 |
|
Targeting the replication stress response through synthetic lethal strategies in cancer medicine
NY Ngoi, MM Pham, DS Tan, TA Yap |
Trends in Cancer | 2021 |
|
Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models
M Dahlmann, G Gambara, B Brzezicha, O Popp, E Pachmayr, L Wedeken, A Pflaume, M Mokritzkij, S Gül-Klein, A Brandl, C Schweiger-Eisbacher, P Mertins, J Hoffmann, U Keilholz, W Walther, C Regenbrecht, B Rau, U Stein |
Molecular Cancer | 2021 |
|
Application of Ovarian Cancer Organoids in Precision Medicine: Key Challenges and Current Opportunities
J Yang, S Huang, S Cheng, Y Jin, N Zhang, Y Wang |
Frontiers in Cell and Developmental Biology | 2021 |
|
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
J Hur, M Ghosh, TH Kim, N Park, K Pandey, YB Cho, SD Hong, NB Katuwal, M Kang, HJ An, YW Moon |
International journal of molecular sciences | 2021 |
|
Ovarian Cancer: Methods and Protocols
P Kreeger |
2021 | |
|
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
H Kim, H Xu, E George, D Hallberg, S Kumar, V Jagannathan, S Medvedev, Y Kinose, K Devins, P Verma, K Ly, Y Wang, RA Greenberg, L Schwartz, N Johnson, RB Scharpf, GB Mills, R Zhang, VE Velculescu, EJ Brown, F Simpkins |
Nature Communications | 2020 |
|
Applications of patient-derived tumor xenograft models and tumor organoids
GJ Yoshida |
Journal of Hematology & Oncology | 2020 |
|
Epithelial/mesenchymal heterogeneity of high‐grade serous ovarian carcinoma samples correlates with miRNA let‐7 levels and predicts tumor growth and metastasis
E Chirshev, N Hojo, A Bertucci, L Sanderman, A Nguyen, H Wang, T Suzuki, E Brito, SR Martinez, C Castañón, S Mirshahidi, ME Vazquez, P Wat, KC Oberg, YJ Ioffe, JJ Unternaehrer |
Molecular Oncology | 2020 |
|
CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma
K Kleinmanns, K Bischof, S Anandan, M Popa, LA Akslen, V Fosse, IT Karlsen, BT Gjertsen, L Bjørge, E McCormack |
EBioMedicine | 2020 |
|
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
C Sun, W Cao, C Qiu, C Li, S Dongol, Z Zhang, R Dong, K Song, X Yang, Q Zhang, B Kong |
Journal of Hematology & Oncology | 2020 |
|
Organoid of ovarian cancer: genomic analysis and drug screening
HD Liu, BR Xia, MZ Jin, G Lou |
Clinical and Translational Oncology | 2020 |
|
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic Malignancies
A Rodriguez-Garcia, P Sharma, M Poussin, AC Boesteanu, NG Minutolo, SB Gitto, DK Omran, MK Robinson, GP Adams, F Simpkins, DJ Powell |
Molecular Therapy | 2020 |
|
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality—An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness
P Gralewska, A Gajek, A Marczak, M Mikuła, J Ostrowski, A Śliwińska, A Rogalska |
International journal of molecular sciences | 2020 |
|
Effects of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis
A Ahmad, AH Mello, B Szczesny, G Törö, M Marcatti, N Druzhyna, L Liaudet, S Tarantini, R Salomao, FG Soriano, C Szabo |
Shock | 2020 |
|
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts
AC Palmer, D Plana, H Gao, JM Korn, G Yang, J Green, X Zhang, R Velazquez, ME McLaughlin, DA Ruddy, C Kowal, J Muszynski, C Bullock, S Rivera, DP Rakiec, GN Elliott, P Fordjour, R Meyer, A Loo, E Kurth, JA Engelman, H Bitter, WR Sellers, JA Williams, PK Sorger |
Cancer research | 2020 |
|
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer
P Gralewska, A Gajek, A Marczak, A Rogalska |
Journal of Hematology & Oncology | 2020 |
|
Modern Approaches to Testing Drug Sensitivity of Patients’ Tumors (Review)
IN Druzhkova, MV Shirmanova, DS Kuznetsova, MM Lukina, EV Zagaynova |
2020 | |
|
Reverse Phase Protein Arrays: From Technical and Analytical Fundamentals to Applications
T Yamada, SS Nishizuka, GB Mills, LA Liotta |
2019 | |
|
Combined MEK and BCL-2/X L Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
C Iavarone, IK Zervantonakis, LM Selfors, S Palakurthi, JF Liu, R Drapkin, UA Matulonis, D Hallberg, VE Velculescu, JD Leverson, D Sampath, GB Mills, JS Brugge |
Molecular cancer therapeutics | 2019 |
|
Xenograft and organoid model systems in cancer research
M Bleijs, M Wetering, H Clevers, J Drost |
The EMBO Journal | 2019 |
|
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
G Damia, M Broggini |
Cancers | 2019 |
|
Current Status of Patient-Derived Ovarian Cancer Models
Y Maru, Y Hippo |
Cells | 2019 |
|
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer
AR Nam, MH Jin, JE Park, JH Bang, DY Oh, YJ Bang |
Cancer Research and Treatment | 2019 |
|
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
Y Fang, DJ McGrail, C Sun, M Labrie, X Chen, D Zhang, Z Ju, CP Vellano, Y Lu, Y Li, KJ Jeong, Z Ding, J Liang, SW Wang, H Dai, S Lee, N Sahni, I Mercado-Uribe, T Kim, K Chen, SY Lin, G Peng, SN Westin, J Liu, MJ O'Connor, TA Yap, GB Mills |
Cancer Cell | 2019 |
|
Chromosomal inversions as a hidden disease-modifying factor for somatic recombination phenotypes
TOSHIFUMI NOMURA, Shotaro Suzuki, TOSHINARI MIYAUCHI, MASAE TAKEDA, Satoru Shinkuma, Yasuyuki Fujita, Wataru Nishie, Masashi Akiyama, Hiroshi Shimizu |
JCI Insight | 2018 |
|
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer
Mehran Makvandi, Austin Pantel, Lauren Schwartz, Erin Schubert, Kuiying Xu, Chia-Ju Hsieh, Catherine Hou, Hyoung Kim, Chi-Chang Weng, Harrison Winters, Robert Doot, Michael Farwell, Daniel Pryma, Roger Greenberg, David Mankoff, Fiona Simpkins, Robert Mach, Lilie Lin |
Journal of Clinical Investigation | 2018 |
|
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
U Testa, E Petrucci, L Pasquini, G Castelli, E Pelosi |
Medicines | 2018 |
|
Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
J Zhang, SS Späth, SL Marjani, W Zhang, X Pan |
2018 | |
|
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
B Garman, IN Anastopoulos, C Krepler, P Brafford, K Sproesser, Y Jiang, B Wubbenhorst, R Amaravadi, J Bennett, M Beqiri, D Elder, KT Flaherty, DT Frederick, TC Gangadhar, M Guarino, D Hoon, G Karakousis, Q Liu, N Mitra, NJ Petrelli, L Schuchter, B Shannan, CL Shields, J Wargo, B Wenz, MA Wilson, M Xiao, W Xu, X Xu, X Yin, NR Zhang, MA Davies, M Herlyn, KL Nathanson |
Cell Reports | 2017 |
|
Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
H Kim, E George, RL Ragland, S Rafail, R Zhang, C Krepler, MA Morgan, M Herlyn, EJ Brown, F Simpkins |
Clinical cancer research | 2016 |
